This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aratana Therapeutics Announces Positive Top-Line Results From AT-001 Dose-Ranging Field Study In Client-Owned Dogs With Osteoarthritis

KANSAS CITY, Kan. and BOSTON, Nov. 20, 2013 /PRNewswire/ --  Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced positive results from its dose-ranging study of AT-001, the company's innovative drug for treating pain in dogs with osteoarthritis.  In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p<0.05) at a once-daily dose.  Aratana expects to move AT-001 forward into the pivotal field effectiveness study in 2014, and then, if the results of the pivotal effectiveness study are favorable, into commercialization upon approval, which is anticipated to be in 2016.

The blinded, placebo-controlled, multi-center dose-ranging study of AT-001 enrolled in excess of 300 client-owned dogs with osteoarthritis.  Dogs were randomized equally into three groups treated with AT-001 (two once per day dose groups and one twice per day dose group) and one group treated with placebo.  Dogs were dosed for 28 days, and effectiveness was determined by a standard protocol utilizing a validated owner-assessed pain score.  Aratana has selected a once-daily dose for further development.

Ernst Heinen, DVM, Ph.D., Head of Drug Evaluation and Development for Aratana Therapeutics, stated, "We are very pleased with these results, which allow us to move forward confidently with a dose of AT-001 that appears safe at therapeutic levels for dogs with osteoarthritis pain."

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, added, "We believe AT-001 has the potential to be an important product in the well-established $260 million pain market in the U.S. alone.  We look forward to continuing our dialogue with the Center for Veterinary Medicine regarding the AT-001 program."

Aratana will discuss these results in more detail when the final study reports are available.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs